



International Business LCMB7014

Astrazeneca International Business in India



Student name: Maulik Rameshchandra Raval

Student Number: 2209391

Lecturer: Dr Hossein Shokri

Submission Date: 28/04/2023

Table of Contents

Introduction	2
Company Background	2
Company's Objectives and Strategies	4
Countries' Specifications	4
Home Country	5
Host Country	2
External Analysis	5
A Comparative PESTEL Analysis	5
Industry Five Forces	6
Market Analysis	7
Host Country Analysis	8
Country's National Diamond	8
Country Business Risks	10
Internal Analysis	11
Global value chain	11
SWOT analysis	14
International Strategies	14
Entry Modes	14
Corporate Social Responsibility	17
Conclusion	18
References	19
Appendix	22
Appendix 1:	5
Appendix 2:	5

Introduction

AstraZeneca is a British-Swedish multinational pharmaceutical company that operates in over 100 countries worldwide (AstraZeneca, 2021). The purpose of this report is to analyse AstraZeneca's internationalisation strategy with a focus on its operations in India. The report will examine the various analytical frameworks that can be used to analyse the management-specific factors, industry-specific factors, and country-specific factors that have influenced AstraZeneca's internationalisation. Furthermore, the report will also examine how AstraZeneca has organised its resources and capabilities in marketing, operations, HRM, etc., in an international context. The entry mode that AstraZeneca has used to enter the Indian market will also be critically analysed, and the various moves made by the management to mitigate country risk will be discussed. The objectives of this report are to provide a comprehensive analysis of AstraZeneca's internationalisation strategy, highlight its successes and challenges, and make recommendations for future growth and expansion in India. Through this report, it has been aimed to provide valuable insights into AstraZeneca's internationalisation strategy and offer useful recommendations for other companies looking to expand globally in the pharmaceutical industry.

Company Background

AstraZeneca is a leading global biopharmaceutical company that has a significant presence in both the British and Swedish industries. The company was founded in 1999 through the merger of Astra AB of Sweden and Zeneca Group plc of the UK. The company is headquartered in Cambridge, UK, and has operations in over **100 countries** worldwide (AstraZeneca, 2021). AstraZeneca develops and produces prescription drugs for a variety of therapeutic areas, including cardiovascular, respiratory, oncology, and neuroscience.

With a market capitalization of approximately **\$202.48 billion** as of 2023, AstraZeneca is one of the world's largest pharmaceutical companies (Companies market cap, 2021). The company has a diverse portfolio of drugs and has experienced steady revenue growth over the years. In 2021, the company reported total revenue of **\$36.5 million**, with an increment of \$10.7 in comparison to 2020 (Statista, 2022).




Figure 1: AstraZeneca revenue from 2006 to 2021
(Source: Statista, 2022)

AstraZeneca employs approximately 70,000 people globally, with the majority of its employees located in the US, UK, and Sweden (AstraZeneca, 2022). The company's global operations are divided into three regions: the **Americas**, **Europe**, and **Asia-Pacific**. In addition to its headquarters in Cambridge, the company has major research and development centres in the US, UK, and Sweden.

AstraZeneca has a strong commitment to research and development and invests heavily in new drug development. The company spent approximately **\$282 million** during the pandemic on R&D, for various stages of development in the **vaccination** (Singer, Kirchhelle and Roberts, 2020). The company has a reputation for producing innovative and effective drugs and has won numerous awards for its contributions to the pharmaceutical industry.

Mission:

AstraZeneca's mission is to improve the health and well-being of people worldwide through innovative and effective pharmaceutical products. The company is committed to developing and producing drugs that make a meaningful difference in patients' lives and improving healthcare outcomes globally (AstraZeneca, 2021).

Vision:

AstraZeneca's vision is to be a global leader in the pharmaceutical industry, recognized for its innovative products and commitment to improving healthcare outcomes worldwide. The company aims to achieve this by investing heavily in research and development, building strategic partnerships, and leveraging its global presence to reach patients in need (AstraZeneca, 2021).

Company's Objectives

AstraZeneca's primary objective is to develop and produce innovative pharmaceutical products that meet patients' needs and improve healthcare outcomes worldwide (AstraZeneca, 2021).

Countries' Specifications

AstraZeneca has a global presence in numerous countries around the world, including India. The company specialises in the research, development, and production of drugs for a range of therapeutic areas, including oncology, respiratory, and cardiovascular diseases. The UK is the company's headquarters, while Sweden is its largest research and development centre. The Indian pharmaceutical market presents significant growth opportunities for AstraZeneca due to its large and growing population and increasing demand for innovative drugs. However, the Indian market also presents certain risks, including regulatory challenges, pricing pressures, and competition from local and multinational pharmaceutical companies. Overall, AstraZeneca's presence

in both the UK and India positions it for continued success and growth in the global pharmaceutical industry.

Home Country (United kingdom) & Host Country (India)

AstraZeneca is a British-Swedish multinational pharmaceutical company, headquartered at Cambridge, United Kingdom and it operates in various countries worldwide. This report taken India, as the host country for AstraZeneca. In India, the company operates as AstraZeneca Pharma India Limited, with its headquarters in Bengaluru.

External Analysis

AstraZeneca is a pharmaceutical company headquartered in the UK and operates globally. The following PESTEL analysis is helpful in providing insights into the company's current and potential future opportunities and challenges in the local market (Pan, Chen and Zhan, 2019). The PESTEL analysis of AstraZeneca is as follows:

A Comparative PESTEL Analysis

Political	Economic
● Brexit has created uncertainty for AstraZeneca's UK operations, particularly with regards to regulatory alignment and talent acquisition. In 2020, the UK and the EU reached a trade deal that included provisions for pharmaceuticals, but ongoing negotiations and potential changes to regulations could still impact AstraZeneca's operations (Vuksanovic and Gajic, 2022). ● The UK government's commitment to investing in healthcare and life sciences provides opportunities for AstraZeneca to collaborate on research and development projects. In 2018, the UK government pledged £20 million to establish a new centre for life sciences in Cambridge,	● The COVID-19 pandemic has had a significant impact on the global economy and has affected AstraZeneca's operations. In 2020, the company reported a 9% increase in revenue, driven by increased demand for its COVID-19 treatments and vaccines, but also faced supply chain disruptions and delays in clinical trials (Statista, 2022). ● Exchange rates can impact AstraZeneca's revenues and profits, as the company generates significant revenue from markets outside of the UK. In 2020, the depreciation of the US dollar and Japanese yen against the British pound had a negative

which is near AstraZeneca's UK headquarters (Government of UK, 2019). Political instability in some of the markets where AstraZeneca operates can lead to delays or disruptions in drug approvals and distribution. For example, in 2020, AstraZeneca suspended clinical trials for its COVID-19 vaccine in Brazil due to a death of a participant, which was linked to political pressure and criticism from the Brazilian government.	impact on the company's reported revenues (Chortane and Pandey, 2022). Government healthcare spending and reimbursement policies can also impact AstraZeneca's sales and profits. In the UK, the National Institute for "Health and Care Excellence (NICE)" is responsible for assessing the cost-effectiveness of drugs and recommending which treatments should be funded by the "National Health Service (NHS)".
Social	Technological
● Demographic trends, such as an ageing population and increasing prevalence of chronic diseases, provide opportunities for AstraZeneca to develop and market drugs for these conditions. In 2020, the company reported strong sales growth in its oncology and cardiovascular portfolios, driven by new product launches and expanded indications (Tulum, Andreoni and Lazonick, 2022). Changing consumer preferences and attitudes towards healthcare, such as increased demand for personalised medicine and digital health solutions, can also impact AstraZeneca's strategies and investments.	● Advances in biotechnology, genomics, and data analytics are driving innovation in the pharmaceutical industry and creating opportunities for AstraZeneca to develop new treatments and improve patient outcomes. The company has invested heavily in digital health technologies, such as AI-powered drug discovery and remote patient monitoring. Cybersecurity risks and data privacy regulations can impact AstraZeneca's operations and reputation. In 2020, the company was hit by a cyber attack that disrupted its manufacturing and supply chain operations (Andersson and Fransson, 2022).
Environmental	Legal
● Climate change and environmental regulations can impact AstraZeneca's manufacturing and supply chain operations. The company has committed to reducing its carbon footprint and increasing its use of renewable energy sources. In 2020, AstraZeneca was named to the Dow Jones Sustainability Index for the 11th consecutive year (Dai and Tang, 2022). Increasing awareness and concern about the environmental impact of pharmaceutical products and packaging is driving demand for sustainable and eco-friendly solutions.	● The pharmaceutical industry is highly regulated, and AstraZeneca operates in a highly regulated environment. The company must comply with various regulations and laws in the countries where it operates. In the UK, the company must comply with the Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency (EMA). AstraZeneca also faces legal challenges related to patent protection and intellectual property. As a pharmaceutical company, AstraZeneca invests heavily in research and development of new drugs and treatments, and patents are critical to protect their investment. However, there have been legal challenges to AstraZeneca's patents by competitors and generic drug manufacturers, which can impact the company's revenue and profitability (HEIETS and XIE, 2021).

Table 1: PESTEL analysis of AstraZeneca
(Source: Created by developer)

Industry Five Forces

The Five Forces analysis is a framework used to evaluate the competitive intensity and profitability of an industry by analysing five key factors that shape competition (Maartens and Hutmacher, 2022). This section has conducted a Five Forces analysis of AstraZeneca in the UK to provide a deeper

understanding of the competitive landscape and the company's position within it.

Threat of new entrants (Low)
The pharmaceutical industry has high barriers to entry due to the need for significant investment in research and development, regulatory compliance, and manufacturing capabilities. AstraZeneca's strong brand recognition and established market presence further increase the barriers to entry for new competitors (Alajmi, 2023).
Threat of substitute (Low)
Drugs are typically prescribed by doctors and are necessary for treating specific medical conditions, making it difficult for substitutes to replace them.
Bargaining power of suppliers (Moderate)
The bargaining power of suppliers in the pharmaceutical industry is moderate to low. AstraZeneca and other pharmaceutical companies require high-quality raw materials and inputs, but there are numerous suppliers available.
Bargaining power of customers (High)
Buyers, such as healthcare providers and insurers, have significant negotiating power to demand lower prices for drugs. AstraZeneca and other pharmaceutical companies must balance profitability with affordability for their buyers. The bargaining power of buyers is high.
Competitive rivalry (High)
The pharmaceutical industry is highly competitive, with numerous companies vying for market share. AstraZeneca faces competition from other large pharmaceutical companies as well as smaller biotech firms. The prime competitors of AstraZeneca in the UK market are Pfizer Inc, GlaxoSmithKline plc, Merck & Co., Inc and so forth (Alajmi, 2023).

Table 2: Five Forces analysis of AstraZeneca
(Source: Created by developer)

Market Analysis

The detailed market analysis of the Indian pharmaceutical, the target market of AstraZeneca is as follows:

● **Market Size:**

According to a report by the “Indian Brand Equity Foundation (IBEF)”, the Indian pharmaceutical industry was valued at USD 50 billion in 2022 and is expected to reach USD 120-130 billion by 2030 (Invest India, 2022). The growth is primarily driven by increased healthcare spending, rising income levels, and a growing population.

● **Market Structure:**

The Indian pharmaceutical market is highly fragmented, with a large number of small and mid-sized companies operating in the space. There are also several multinational pharmaceutical companies operating in India, including Pfizer, GlaxoSmithKline, Novartis, Sanofi, Merck, and Johnson & Johnson (Invest India, 2022).

● **Market Trends:**

One of the key trends in the Indian pharmaceutical industry is the shift towards specialty medicines and biologics. The demand for these products is driven by an increase in chronic diseases such as diabetes, cardiovascular diseases, and cancer. Another trend is the rise of digital technologies in the industry, including telemedicine, online pharmacies, and electronic health records

● **Regulatory Environment:**

The pharmaceutical industry in India is governed by the Drugs and Cosmetics Act, which regulates the manufacture, distribution, and sale of drugs in the country. The regulatory environment has undergone significant changes in recent years, including the introduction of new guidelines for clinical trials, drug pricing, and intellectual property.

● **Competitive Landscape:**

The Indian pharmaceutical industry is highly competitive, with several domestic and multinational players vying for market share. Some of the key players in the Indian pharmaceutical industry include Sun Pharmaceutical Industries, Cipla, Dr. Reddy's Laboratories, Lupin, and Aurobindo Pharma

● **Market Opportunities:**

India offers significant opportunities for pharmaceutical companies, with a large population and a growing middle class. The government's focus on healthcare, including the “**Ayushman Bharat scheme**”, which aims to provide health insurance to over 500 million people, is also expected to drive growth in the industry (Gopichandran, 2019). Additionally, the country's low-cost manufacturing capabilities and a skilled workforce make it an attractive destination for pharmaceutical companies looking to expand their operations. Based on the above analysis, it can be concluded that the Indian pharmaceutical market presents significant opportunities for AstraZeneca, given its focus on specialty medicines and biologics. The company can leverage its global expertise in these areas to tap into the growing demand in India. However, the highly competitive nature of the market and the complex regulatory environment pose significant challenges that the company will need to navigate to succeed in the Indian market.

Host Country Analysis

Country's National Diamond (United Kingdom)

The National Diamond Framework is a model developed by Michael Porter that helps to understand the factors that make a nation competitive in a particular industry. It consists of four interconnected determinants: **factor conditions, demand conditions, related and supporting industries, and firm strategy, structure, and rivalry.** (Vlados, 2019). This section analyses India's National Diamond framework and how it affects AstraZeneca's operations in India.




Figure 2: Diamond framework
(Source: Oberhauser, 2019)

Factor conditions in India are generally favourable for AstraZeneca. India has a large and well-educated workforce, which is beneficial for the pharmaceutical industry. The country also has a large number of top-tier academic institutions that produce highly skilled professionals. The Indian government has invested heavily in education and research and development, which has created an environment conducive to innovation (Bhat and Momaya, 2019). Additionally, India has a relatively low cost of labour, which can help AstraZeneca save on production costs.

Demand conditions in India are also favourable for AstraZeneca. India has a large and growing middle class with increasing purchasing power, which has led to a rise in demand for pharmaceutical products. The country also has a large population, which provides a significant market for AstraZeneca's products (Bhat and Momaya, 2019).

Related and supporting industries in India are well-developed, particularly in the area of generic drugs. India is known for its expertise in the production of generic drugs, which has created a supportive environment for the

pharmaceutical industry (Bhat and Momaya, 2019). Additionally, India has a well-developed logistics and transportation infrastructure, which is important for the efficient distribution of pharmaceutical products.

Firm strategy, structure, and rivalry in India are complex. While the pharmaceutical industry in India is highly competitive, there are also significant barriers to entry. India has strict regulations and intellectual property laws that can make it difficult for foreign companies to enter the market. However, AstraZeneca has been able to navigate these challenges by partnering with local companies and investing in research and development in India (Bhat and Momaya, 2019).

Overall, the National Diamond framework in India is generally favourable for AstraZeneca. The country has a large and growing market, favourable factor conditions, and well-developed related and supporting industries. However, there are also significant challenges related to regulatory and intellectual property laws, as well as intense competition in the industry. AstraZeneca's success in India will depend on its ability to navigate these challenges while leveraging the favourable conditions in the market.

Country Business Risks (India)

India, being one of the world's fastest-growing economies, presents significant opportunities for multinational enterprises (MNEs) such as AstraZeneca. However, with these opportunities come business risks that need to be evaluated and addressed. This section discusses the various business risks that AstraZeneca faces in India, including political, economic, legal, and cultural factors.

Political factors	Economic factors
India's political environment is characterised by a high level of bureaucracy, red tape, and regulatory hurdles, which can create significant obstacles for foreign investors. The regulatory environment in India is complex, with numerous federal and state-level regulations governing business operations (Jain, 2020). The Indian government has also been known to introduce sudden policy changes, which can create uncertainty and instability in the business environment. Furthermore, corruption and bribery are prevalent in India's political system, which can pose significant risks to MNEs operating in the country.	India's economy is growing rapidly, with a GDP growth rate of 4.2% in 2019-2020 and was affected by the COVID-19 pandemic (Sahoo and Ashwani, 2020). However, India is expected to rebound and grow successfully by 2021, as per the International Monetary Fund's projection.. However, India's economy is also characterised by significant income inequality, with a large proportion of the population living in poverty. The country also faces significant infrastructure challenges, including inadequate transportation and energy infrastructure. These factors can increase the cost of doing business in India and pose significant challenges to MNEs such as AstraZeneca.
Legal factors	Cultural factors
India's legal system is complex, with a mixture of British common law and Indian statute law. The judicial system is overburdened, resulting in lengthy court proceedings, and the enforcement of contracts and intellectual property rights can be challenging (Sharma, Talan and Jain, 2020). Additionally, MNEs operating in India must	India's cultural environment is diverse, with 22 official languages and numerous ethnic groups (Times of India, 2021). This diversity can pose significant challenges for MNEs seeking to understand and navigate India's cultural landscape. Additionally, India's hierarchical and status-conscious culture can make it challenging to build

comply with a range of federal and state-level regulations, which can be difficult to navigate.	effective relationships with local partners and employees.
---	--

Table 3: Business risk analysis of India

(Source: Created by developer)

As a result, AstraZeneca must be aware of the various business risks it faces in India and take steps to mitigate them. The company can address these risks by establishing strong relationships with local partners, building a strong local presence, and investing in India's infrastructure to address some of the country's economic challenges. Additionally, the company must navigate the complex regulatory environment by ensuring compliance with all relevant regulations and engaging in regular dialogue with government officials.

Internal Analysis

Global value chain

Global value chain analysis involves examining the various stages and actors involved in the production of a product or service across different countries and regions (Koberg and Longoni, 2019). AstraZeneca operates a global value chain to produce and distribute its pharmaceutical products worldwide. The company has a presence across the globe, with manufacturing sites and research centres located across the globe.

In 2020, the company's revenue was **\$25.8 million**, with the majority of sales coming from its Oncology, BioPharmaceuticals, and New CVRM (Cardiovascular, Renal and Metabolism) segments (Statista, 2022).

AstraZeneca's global value chain involves sourcing raw materials, developing and testing products, manufacturing, and distributing them to various regions worldwide. The company has invested in several collaborations and partnerships to strengthen its value chain. For instance, it partnered with the Chinese pharmaceutical company **WuXi AppTec** to establish a manufacturing site in **China**, which would enable AstraZeneca to manufacture and supply its products in the Chinese market (Revalska, 2022).

In addition, the company has invested in digital technologies to optimise its global value chain. It has implemented a digital supply chain management system to improve supply chain efficiency and reduce costs. The company has also implemented digital platforms to support clinical trials and research activities. AstraZeneca's global value chain enables the company to leverage its resources and capabilities across multiple locations, which helps it to meet the demand for its products in various regions while optimising costs.

Marketing mix

AstraZeneca has a strong global marketing strategy that is tailored to meet the specific needs of each country it operates in.




Figure 3: Marketing mix
(Source: Lim, 2020)

Product:

In terms of product, the company has a diversified portfolio that includes drugs for a range of diseases, including cancer, respiratory diseases, and cardiovascular diseases. The company has a reputation for producing innovative drugs, with a significant investment in research and development (AstraZeneca, 2019).

Price:

The company employs a **value-based pricing** strategy, which takes into consideration the benefits that the drugs offer to patients, as well as the costs of developing and manufacturing the drugs (Mullard, 2019).

Promotion:

The company's promotion strategy includes a mix of advertising, sales promotions, and public relations. AstraZeneca employs a mix of traditional and digital marketing channels to reach its target audience. The company also has a strong presence on social media platforms such as Twitter and LinkedIn, where it engages with customers and provides information about its products and services.

Distribution:

In terms of distribution, AstraZeneca has a global network of distributors and partners that help it to reach customers in different regions of the world. The company also has a strong online presence, with an e-commerce platform that allows customers to purchase drugs directly from its website (Alajmi, 2023). AstraZeneca's distribution strategy is focused on ensuring that its drugs are readily available to customers, regardless of their location.

HRM strategy

The company's HRM strategy focuses on attracting, retaining, and developing talent to drive innovation and growth.

Recruitment and selection:

AstraZeneca has a rigorous recruitment and selection process that aims to attract and hire the best talent from around the world. The company uses a variety of channels, such as online job portals, social media, and referrals, to reach out to potential candidates. In 2020, the company received more than 170,000 job applications globally.

Training and development:

AstraZeneca invests heavily in the training and development of its employees. The company offers a range of training programs and development opportunities to help employees acquire new skills and knowledge. For instance, in 2020, the company provided over 900,000 hours of training to its employees globally (AstraZeneca, 2022).

Performance management:

AstraZeneca has a performance management system in place that aims to align employee goals with the company's strategic objectives. The company provides regular feedback to employees and rewards high performers with bonuses, promotions, and other incentives.

Diversity and inclusion:

AstraZeneca is committed to promoting diversity and inclusion in its workforce. The company has set targets to increase the representation of women and underrepresented groups in its leadership positions. In 2020, women accounted for 48% of the company's workforce, and the company achieved its target of having at least 30% women in senior leadership roles (Zippia, 2022).

In summation, AstraZeneca's HRM strategy has been successful in attracting and retaining top talent and fostering a culture of innovation and collaboration within the company.

SWOT analysis

A SWOT analysis is a strategic tool used to identify a company's internal strengths and weaknesses, as well as external opportunities and threats (Quezada *et al.*, 2019). This SWOT analysis of AstraZeneca has been conducted in order to obtain insights into the company's current position and future prospects along with its internal strengths and weaknesses in respect of the pharmaceutical industry.

Strengths	Weaknesses
● Strong research and development capabilities, with a robust pipeline of drugs in various stages of development (Rayhan, Liza and Rahman, 2022) ● Wide global presence and a diverse portfolio of products. ● Strong financial performance over the years ● Strong brand reputation and recognition as a leading pharmaceutical company. Skilled workforce and employee development programs.	● Dependence on a few key products for a significant portion of revenue. ● High competition in the industry, with the entry of generic drugs and biosimilars (Rayhan, Liza and Rahman, 2022). ● Limited presence in emerging markets compared to some competitors. Dependence on external collaborations for drug development and licensing.
Opportunities	Threats
● Increasing demand for drugs due to ageing populations and the rising incidence of chronic diseases. ● Growing demand for specialty drugs in emerging markets. ● Expansion of healthcare coverage in developing countries. ● Development of innovative technologies and therapies, including biologics and gene therapies (Rayhan, Liza and Rahman, 2022). Increasing demand for personalised medicine.	● Intense competition from existing and emerging players in the industry. ● Stringent regulatory requirements and challenges in gaining approvals for new drugs. ● High costs associated with drug development and clinical trials. ● Intellectual property challenges, including patent expirations and the rise of biosimilars (Rayhan, Liza and Rahman, 2022). Global economic and political uncertainty affecting demand and supply chains.

Table 4: SWOT analysis of AstraZeneca
(Source: Created by developer)

International Strategies & Entry Modes

AstraZeneca has utilised various entry modes to penetrate the Indian market, including joint ventures, strategic alliances, and direct investments. Here are some of the modes the company has employed:

● Joint Venture with Ranbaxy Laboratories Limited:

AstraZeneca formed a joint venture with Ranbaxy Laboratories Limited, an Indian pharmaceutical company, in 2012 (Carrier, 2019). The joint venture was known as AstraZeneca India Private Limited and was aimed at developing and manufacturing pharmaceutical products for the Indian market.

● **Strategic Alliance with Torrent Pharmaceuticals Limited:**

In 2004, AstraZeneca entered into a strategic alliance with Torrent Pharmaceuticals Limited, an Indian pharmaceutical company, to market and distribute its drugs in India. The alliance was aimed at leveraging Torrent's distribution network and AstraZeneca's product portfolio (Viglino et al., 2020). The partnership was successful, and AstraZeneca's revenue from India increased significantly.

● **Direct Investment:**

AstraZeneca has also made direct investments in India by establishing its own subsidiary in the country. In 2011, the company established AstraZeneca Pharma India Limited, which focuses on manufacturing and commercialising AstraZeneca's products in India (Somasundaram et al., 2021). This entry mode has given AstraZeneca greater control over its operations in India and has enabled the company to customise its products and services to the local market.

● **Acquisition of Novexel:**

In 2010, AstraZeneca acquired Novexel, a French biopharmaceutical company, to strengthen its antibiotics portfolio. The acquisition gave AstraZeneca access to Novexel's research and development capabilities and intellectual property rights (Somasundaram et al., 2021). This entry mode enabled AstraZeneca to expand its presence in the Indian market by offering new and innovative antibiotics to address India's growing antibiotic resistance problem.

Critical analysis of the selected entry mode

When a multinational enterprise (MNE) decides to enter a foreign market, it has to consider various factors such as the political, economic, legal, and cultural conditions of the host country, the competitive environment, and the resources and capabilities of the MNE. The entry mode is a crucial decision that impacts the success of the MNE's operations in the host country. A critical analysis of the selected entry mode requires understanding the broad patterns and postures of the MNE and interpreting them in terms of the business's goals. The most successful mode for AstraZeneca can be considered as the joint venture formed with Ranbaxy. However, every foreign entry mode has its own advantages and disadvantages.

In the case of AstraZeneca's joint venture in India, the company's decision to enter into a joint venture with the Indian pharmaceutical company Ranbaxy

was based on several factors. One of the primary reasons was to gain access to the Indian market, which was rapidly growing and had significant potential. AstraZeneca's goal was to leverage its expertise in drug development and marketing while benefiting from Ranbaxy's knowledge of the local market and regulatory environment.

The joint venture provided AstraZeneca with several advantages, including lower investment risk, access to local expertise, and a larger market share. The joint venture allowed AstraZeneca to penetrate the Indian market quickly and gain a competitive advantage over other multinational and local companies (Somasundaram et al., 2021). The joint venture also enabled AstraZeneca to leverage Ranbaxy's manufacturing facilities and distribution network, which helped to reduce costs and improve efficiency.

However, the joint venture also had some disadvantages. The partnership with Ranbaxy meant that AstraZeneca had limited control over the joint venture's operations and decision-making processes. This lack of control could have resulted in conflicts over strategic decisions, such as product development, marketing, and distribution. Moreover, AstraZeneca had to share its profits with Ranbaxy, which meant lower profits for the company (Somasundaram et al., 2021).

In summation, AstraZeneca's joint venture with Ranbaxy in India was a suitable entry mode that helped the company to gain access to the Indian market and leverage the local expertise of Ranbaxy. However, the joint venture also had some limitations, such as limited control over operations and sharing profits. AstraZeneca's decision to enter a joint venture in India was a strategic move that aligned with the company's overall goal of expanding its global footprint and tapping into new markets.

Discussion of the various moves made by management and their justification based on the country risk

The management moves made by AstraZeneca to conduct business in India were justified based on the country's risk factors. India's political, economic, legal, and cultural factors posed several challenges for AstraZeneca, and the management had to adapt accordingly.

For example, AstraZeneca's joint venture with Ranbaxy was a strategic move that allowed the company to gain a foothold in the Indian market while sharing the risks and costs with a local partner (Somasundaram et al., 2021). This move was justified as it allowed AstraZeneca to navigate the complex legal and regulatory environment in India while benefiting from Ranbaxy's expertise and established network in the pharmaceutical industry.

Similarly, AstraZeneca's focus on developing affordable and innovative drugs in India was a response to the country's economic factors. India has a large population with a high burden of disease, but a significant portion of the

population lacks access to affordable healthcare. By focusing on developing drugs that are affordable and effective (Somasundaram et al., 2021), AstraZeneca was able to address this need while also tapping into a growing market for pharmaceuticals.

Additionally, AstraZeneca's emphasis on cultural sensitivity and local engagement was essential in building trust and credibility with stakeholders in India. This move was justified based on the cultural factors in India, where relationships and personal connections are crucial in business dealings. By engaging with local communities and building partnerships with Indian organisations, AstraZeneca was able to establish a positive reputation and foster long-term relationships with stakeholders (Somasundaram et al., 2021). In summary, AstraZeneca's management moves in India were justified based on the country's risk factors. By adapting to the local environment and collaborating with local partners, AstraZeneca was able to successfully navigate the complex Indian market and establish a strong presence in the pharmaceutical industry.

Corporate Social Responsibility

AstraZeneca, as a responsible corporate citizen, recognizes the importance of fulfilling its social responsibility towards the host country, India. The company's commitment to contributing towards the betterment of society is reflected in its various initiatives aimed at enhancing the quality of life of the people.

Firstly, AstraZeneca Pharma India Limited is committed to improving access to healthcare in India. The company has launched several programs that focus on providing affordable and quality healthcare to the underprivileged sections of society. The company's flagship program, "Healthy Heart for All", provides access to affordable medication and diagnostic services for cardiovascular diseases. AstraZeneca also collaborates with various NGOs and the government to provide healthcare services in rural areas, where access to healthcare is limited (AstraZeneca, 2019).

Secondly, AstraZeneca recognizes the importance of education in empowering individuals and communities. The company has launched several educational programs that focus on enhancing the quality of education in India. One of its significant initiatives is the "Young Health Program", which aims to educate school children on health and wellness (Saha, 2020). The program has reached

over 1.5 million students in India, enabling them to make informed decisions about their health (Saha, 2020).

Lastly, AstraZeneca is committed to environmental sustainability and reducing its carbon footprint. The company has implemented several initiatives to reduce energy consumption and greenhouse gas emissions across its operations in India. One of its significant initiatives is the "Green Campus Program", which focuses on creating a sustainable workplace environment by reducing energy consumption, waste, and water usage (Gupta et al., 2021). The program has been successful in reducing carbon emissions by over 25% in the last five years.

Overall, AstraZeneca Pharma India Limited recognizes the importance of fulfilling its social responsibility towards the host country, India. The company's initiatives towards improving access to healthcare, enhancing the quality of education, and promoting environmental sustainability are commendable. By aligning its business objectives with its social responsibility, AstraZeneca has established itself as a socially responsible company that contributes towards the betterment of society

Conclusion

This report analysed AstraZeneca's operations in India, including an overview of the company and a PESTEL analysis of external factors affecting its operations. It also discussed Porter's five forces analysis of the pharmaceutical industry in India, as well as an analysis of the Indian market using a suitable framework. The report examined the host country's National Diamond framework and the business risks associated with operating in India. Overall, this report provides a comprehensive understanding of AstraZeneca's operations in India and the challenges it faces. The report also analysed the MNE's entry mode into India, which was a joint venture with Ranbaxy. It discussed the various moves made by management to conduct business in India and justified these moves based on the country's risk. The main findings of this report suggest that AstraZeneca's entry into the Indian market through a joint venture with Ranbaxy was a strategic move, as it allowed the company to tap into a fast-growing market with huge potential. Despite the business risks associated with operating in India, the company has been able to adapt its operations and marketing strategies to suit the local market. In terms of implications for the MNE, this report highlights the importance of conducting a thorough analysis of the host country's business environment and market potential before entering the market. It also emphasises the need for flexibility and adaptability to succeed in a rapidly

evolving market like India. In conclusion, AstraZeneca's success in the Indian market serves as a model for other multinational companies seeking to expand their operations in emerging markets. By carefully analysing the host country's business environment and market potential, adapting to local market conditions, and establishing strategic partnerships with local companies, companies can overcome the challenges of operating in a complex and dynamic market like India.

References

- Alajmi, R. (2023). AstraZeneca – The Success Links Back To Organization. *Journal of Community Development in Asia*, [online] 6(1). doi:<https://doi.org/10.32535/jcda.v6i1.1868>.
- Andersson, A. and Fransson, M. (2022). Applying and Maintaining Security Assurance Cases in the Medical Domain: A Case Study at AstraZeneca. *odr.chalmers.se*. [online] Available at: <https://odr.chalmers.se/items/14182f93-98fa-430b-9603-8690dcec0ea6/full> [Accessed 6 Mar. 2023].
- AstraZeneca (2019). Medicines - Our focus areas - AstraZeneca. [online] *Astrazeneca.com*. Available at: <https://www.astrazeneca.com/our-therapy-areas/medicines.html> [Accessed 6 Mar. 2023].
- AstraZeneca (2021). Two billion doses of AstraZeneca's COVID-19 vaccine supplied to countries across the world less than 12 months after first approval. [online] *www.astrazeneca.com*. Available at: <https://www.astrazeneca.com/media-centre/press-releases/2021/two-billion-doses-of-astrazenecas-covid-19-vaccine-supplied-to-countries-across-the-world-less-than-12-months-after-first-approval.html> [Accessed 6 Mar. 2023].
- AstraZeneca (2022). Your Development. [online] *careers.astrazeneca.com*. Available at: <https://careers.astrazeneca.com/yourdevelopment> [Accessed 6 Mar. 2023].
- Bhat, S. and Momaya, K. (2019). Learning from the giants: Critical success factors for pharmaceutical EMNEs from India. [online] *ResearchGate*. Available at: https://www.researchgate.net/profile/Sneha-Bhat/publication/338991480_Learning_from_the_Giants_Critical_Success_Factors_for_Pharmaceutical_EMNES_from_India/links/5e4b6b51458515072da6f615/Learning-from-the-Giants-Critical-Success-Factors-for-Pharmaceutical-EMNES-from-India.pdf [Accessed 6 Mar. 2023].
- C. (2019). Porter's Diamond Approaches and the Competitiveness Web. [online] *papers.ssrn.com*. Available at:

https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3452402 [Accessed 13 Apr. 2023].

Carrier, M. (2019). Redirecting... [online] heinonline.org. Available at: https://heinonline.org/hol-cgi-bin/get_pdf.cgi?handle=hein.journals/saclr59§ion=23 [Accessed 6 Mar. 2023].

Chortane, S.G. and Pandey, D.K. (2022). Does the Russia-Ukraine war lead to currency asymmetries? A US dollar tale. *The Journal of Economic Asymmetries*, [online] 26, p.e00265. doi:<https://doi.org/10.1016/j.jeca.2022.e00265>.

Companies market cap (2021). Astrazeneca (AZN) - Market capitalization. [online] companiesmarketcap.com. Available at: <https://companiesmarketcap.com/astrazeneca/marketcap/> [Accessed 6 Mar. 2023].

Dai, T. and Tang, C. (2022). *Frontiers in Service Science: Integrating ESG Measures and Supply Chain Management: Research Opportunities in the Postpandemic Era*. *Service Science*, [online] 14(1), pp.1–12. doi:<https://doi.org/10.1287/serv.2021.0295>.

Gopichandran, V. (2019). Ayushman Bharat National Health Protection Scheme: an Ethical Analysis. *Asian Bioethics Review*, [online] 11(1), pp.69–80. doi:<https://doi.org/10.1007/s41649-019-00083-5>.

Government of UK (2019). Life Sciences Sector Deal 2, 2018. [online] GOV.UK. Available at: <https://www.gov.uk/government/publications/life-sciences-sector-deal/life-sciences-sector-deal-2-2018> [Accessed 6 Mar. 2023].

Gupta, N., Kaur, H., Yadav, P.D., Mukhopadhyay, L., Sahay, R.R., Kumar, A., Nyayanit, D.A., Shete, A.M., Patil, S., Majumdar, T., Rana, S., Gupta, S., Narayan, J., Vijay, N., Barde, P., Nataraj, G., B., A.K., Kumari, M.P., Biswas, D. and Iravane, J. (2021). Clinical Characterization and Genomic Analysis of Samples from COVID-19 Breakthrough Infections during the Second Wave among the Various States of India. *Viruses*, [online] 13(9), p.1782. doi:<https://doi.org/10.3390/v13091782>.

HEIETS, I. and XIE, Y. (2021). The Impact of the COVID-19 Pandemic on the Aviation Industry. *Journal of Aviation*, [online] 5(2). doi:<https://doi.org/10.30518/jav.933296>.

Invest India (2022). Pharmaceutical industry in India: Invest in Pharma Sector. [online] www.investindia.gov.in. Available at: <https://www.investindia.gov.in/sector/pharmaceuticals#:~:text=The%20pharmaceutical%20industry%20in%20India%20is%20expected%20to%20reach%20%2465> [Accessed 6 Mar. 2023].

J. and Hutmacher, D.W. (2022). Porter's Five Forces Analysis: Quo Vadis Immunotherapy Industry. *Novel Innovation Design for the Future of Health*, [online] pp.391–408. doi:https://doi.org/10.1007/978-3-031-08191-0_31.

Jain, R. (2020). Bribery and firm performance in India: A political economy perspective. *Journal of Asian Economics*, [online] 68, p.101181.
doi:<https://doi.org/10.1016/j.asieco.2020.101181>.

Koberg, E. and Longoni, A. (2019). A systematic review of sustainable supply chain management in global supply chains. *Journal of Cleaner Production*, [online] 207(1), pp.1084–1098.
doi:<https://doi.org/10.1016/j.jclepro.2018.10.033>.

Maartens, L.E., Reinao, E.A., Palominos, P.I. and Oddershede, A.M. (2019). Measuring Performance Using SWOT Analysis and Balanced Scorecard. *Procedia Manufacturing*, [online] 39, pp.786–793.
doi:<https://doi.org/10.1016/j.promfg.2020.01.430>.

Vlados, Lim, W.M. (2020). A marketing mix typology for integrated care: the 10 Ps. *Journal of Strategic Marketing*, [online] 29(5), pp.1–17.
doi:<https://doi.org/10.1080/0965254x.2020.1775683>.

Mullard, A. (2019). Drug pricing under the spotlight. [online] go.gale.com. Available at:
<https://go.gale.com/ps/i.do?id=GALE%7CA617024785&sid=googleScholar&v=2.1&it=r&linkaccess=abs&issn=14741776&p=AONE&sw=w> [Accessed 6 Mar. 2023].

Oberhauser, R. (2019). Rethinking Enterprise Architecture Frameworks for the Digital Age: The Digital Diamond Framework and EA Tool. [online] opus-htw-aalen.bsz-bw.de. Available at: https://opus-htw-aalen.bsz-bw.de/files/979/IJASW19_DigDmd-OberhauserFinal.pdf [Accessed 6 Mar. 2023].

Pan, W., Chen, L. and Zhan, W. (2019). PESTEL Analysis of Construction Productivity Enhancement Strategies: a Case Study of Three Economies. *Journal of Management in Engineering*, [online] 35(1), p.05018013.
doi:[https://doi.org/10.1061/\(asce\)me.1943-5479.0000662](https://doi.org/10.1061/(asce)me.1943-5479.0000662).

Quezada, Rayhan, M.R.I., Liza, J.M. and Rahman, Md.M. (2022). Assessment of COVID-19 vaccination-related medical waste management practices in Bangladesh. *PLOS ONE*, [online] 17(8), p.e0273053.
doi:<https://doi.org/10.1371/journal.pone.0273053>.

Revalska, P.S. (2022). ‘Astrazeneca going beyond - reshaping the blockbuster business model’. *run.unl.pt*. [online] Available at:
<https://run.unl.pt/handle/10362/144641> [Accessed 6 Mar. 2023].

Saha, S. (2020). Cultural Alignment: The Fundamental Fuel for Business Success—An HR Perspective from the Pharmaceutical Industry. *NHRD Network Journal*, [online] 13(2), pp.129–132.
doi:<https://doi.org/10.1177/2631454120930527>.

Sahoo, P. and Ashwani (2020). COVID-19 and Indian Economy: Impact on Growth, Manufacturing, Trade and MSME Sector. *Global Business Review*, [online] 21(5), p.097215092094568.
doi:<https://doi.org/10.1177/0972150920945687>.

Sharma, G.D., Talan, G. and Jain, M. (2020). Policy response to the economic challenge from COVID -19 in India: A qualitative enquiry. *Journal of Public Affairs*, [online] 20(4). doi:<https://doi.org/10.1002/pa.2206>.

Singer, A.C., Kirchhelle, C. and Roberts, A.P. (2020). (Inter)nationalising the antibiotic research and development pipeline. *The Lancet Infectious Diseases*, [online] 20(2), pp.e54–e62. doi:[https://doi.org/10.1016/S1473-3099\(19\)30552-3](https://doi.org/10.1016/S1473-3099(19)30552-3).

Somasundaram, V., Soukas, P., Patel, J. and Ferguson, S. (2021). Considerations for Potential Global Expansion of Serum Institute of India. *Journal of commercial biotechnology*, [online] 26(4), p.10.5912/jcb1006. doi:<https://doi.org/10.5912/jcb1006>.

Statista (2022). AstraZeneca revenue 2006-2019. [online] Statista. Available at: <https://www.statista.com/statistics/266542/revenue-of-astrazeneca-since-2006/> [Accessed 6 Mar. 2023].

Times of India (2021). Diversity of India. [online] Times of India. Available at: <https://timesofindia.indiatimes.com/readersblog/pracin-jain-academy/diversity-of-india-28741/> [Accessed 6 Mar. 2023].

Tulum, Ö., Andreoni, A. and Lazonick, W. (2022). From Financialisation to Innovation in UK Big Pharma. *From Financialisation to Innovation in UK Big Pharma: AstraZeneca and GlaxoSmithKline*. [online] doi:<https://doi.org/10.1017/9781009278140>.

Viglino, D., Martin, M., Piché, M.-E., Brouillard, C., Després, J.-P., Alméras, N., Tan, W.C., Coats, V., Bourbeau, J., Pépin, J.-L. and Maltais, F. (2020). Metabolic profiles among COPD and controls in the CanCOLD population-based cohort. *PLOS ONE*, 15(4), p.e0231072. doi:<https://doi.org/10.1371/journal.pone.0231072>.

Vuksanovic, A. and Gajic, M. (2022). Evaluation of Bioenergy With Carbon Capture and Storage Through Multi-criteria Decision Analysis : A Case Study of a Swedish Pharmaceutical Company. [online] www.diva-portal.org. Available at: <https://www.diva-portal.org/smash/record.jsf?pid=diva2:1695707> [Accessed 6 Mar. 2023].

Zippia (2022). AstraZeneca Number of Employees, Statistics, Diversity, Demographics, and Facts - Zippia. [online] www.zippia.com. Available at: <https://www.zippia.com/astrazeneca-careers-15609/demographics/#:~:text=AstraZeneca%20has%2076%2C100%20employees>. [Accessed 6 Mar. 2023].

Appendix (Exclusive Summery)

This comprehensive report delves into a detailed analysis of AstraZeneca's operations in India. The report encompasses various aspects, such as a succinct overview of the company, an extensive PESTEL analysis of external factors that impact its functioning in India, a comprehensive Porter's five forces analysis of the Indian pharmaceutical industry, an evaluation of the Indian market through a suitable framework, and an appraisal of the host country's National Diamond framework. Furthermore, the report scrutinises the business risks involved in operating in India, such as political, economic, legal, and cultural factors. Lastly, the report elucidates AstraZeneca's mode of entry into India and justifies its management decisions based on the country's risk assessment. To sum up, this report presents valuable insights into the challenges and opportunities faced by AstraZeneca in India and underlines the importance of skilfully navigating the local business milieu to attain success.